CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS
On May 22, 2017, Celgene Corporation issued a press release
announcing certain results of its phase III RADIANCE trial,
evaluating the efficacy and safety of ozanimod, an
investigational oral, selective S1P 1 and 5 receptor modulator,
in patients with relapsing multiple sclerosis. Attached hereto
and incorporated herein by reference as Exhibit 99.1 is the press
release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 Press Release dated May 22, 2017
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information
CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session 00.00 at 116.93 with 3,093,067 shares trading hands.